Target intelligence / Profile preview

Plasma membrane calcium-transporting ATPase 4 (PMCA4), isoform b (PMCA4b)

Target
PMCA4b
Molecular classification
Transporter, Enzyme, P-type ATPase
01

Overview

Plasma membrane calcium-transporting ATPase 4, isoform b (PMCA4b), is a member of the P-type ATPase family responsible for the high-affinity, active transport of calcium ions out of eukaryotic cells using energy from ATP hydrolysis[2][8]. The gene encoding PMCA4b is ATP2B4. PMCA4b is widely expressed and is subject to complex regulation via alternative splicing, interaction with calmodulin, and partner proteins, especially through its unique PDZ-binding motif present in the "b" isoform[1][3][4]. It plays a crucial role in maintaining low cytosolic Ca2+ concentration and is involved in fine-tuning signaling pathways controlling muscle contraction, neuronal activity, sperm function, cell migration, and shape. Pathogenic mutations lead to neurological disorders (familial spastic paraplegia) and male infertility has been reported in knockout models[1][2][5]. PMCA4b also inhibits melanoma cell migration and modulates nitric oxide synthase activity in the heart, linking it to cancer and cardiovascular physiology[1][10]. While PMCA4b has no specific approved drugs targeting it, its central role in Ca2+ signaling and disease makes it a potential therapeutic target[4].

Other names
Plasma membrane calcium ATPase isoform 4bATPase plasma membrane Ca2+ transporting 4bATP2B4 (gene name)PMCA4bPlasma membrane Ca2+ pump 4b
02

Mechanism of action

Inhibition of the pump impairs calcium extrusion, increases intracellular Ca2+, potentially disrupting cellular signaling[4].

03

Biological functions

Calcium extrusion from cellsRegulation of intracellular calcium homeostasisSignal transduction modulationRegulation of sperm motilityRegulation of cell shape and migration
04

Disease associations

Neurodegenerative disease (e.g., spastic paraplegia)Cardiovascular diseaseCancer (e.g., melanoma, breast cancer cell migration)Male infertility
05

Safety considerations

Non-selective inhibition may disrupt calcium homeostasis widely, with potential for adverse effects in the heart, nervous system, and fertility[4][9].
06

Interacting drugs

No clinically approved drugs are known to selectively target PMCA4b; general pump inhibitors (such as vanadate or caloxins) have been studied only experimentally[4].
07

Biomarkers

Mutations in the ATP2B4 gene (such as R268Q) as biomarkers for familial spastic paraplegia and possibly other rare defects[1][2].

Beyond the preview

Go deeper on Plasma membrane calcium-transporting ATPase 4 (PMCA4), isoform b (PMCA4b).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasma membrane calcium-transporting ATPase 4 (PMCA4), isoform b (PMCA4b).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call